Investigating genetic risks associated with Methamphetamine Use Disorder
L-type Calcium Channel SNP rs1006737: characterizing the genetic risks in MUD (Methamphetamine Use Disorder)
This study is looking at how differences in a specific gene might affect how methamphetamine impacts the brain, especially when it comes to brain inflammation and thinking skills during recovery, with the goal of finding better ways to help people dealing with meth addiction.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Hawaii at Manoa NIH-funded |
| Lab location | 1 site (Honolulu, United States) |
| Project ID | NIH-10668210 on NIH RePORTER |
What this research studies
This research focuses on understanding how genetic variations in the L-type calcium channel gene may influence the effects of methamphetamine on the brain. It examines the relationship between methamphetamine use, brain inflammation, and cognitive dysfunction, particularly during periods of abstinence. By studying these genetic factors, the research aims to uncover mechanisms that could lead to improved treatment strategies for individuals struggling with methamphetamine addiction.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of methamphetamine use who may be experiencing cognitive dysfunction or other related mental health issues.
Not a fit: Patients who have not used methamphetamine or do not have any cognitive dysfunction related to substance use may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for individuals with Methamphetamine Use Disorder by targeting genetic factors that influence recovery.
How similar studies have performed: While the specific genetic focus on L-type calcium channels in the context of methamphetamine use is novel, similar research has shown that understanding genetic influences can lead to advancements in treatment for other substance use disorders.
Where this research is happening
Honolulu, United States
- University of Hawaii at Manoa — Honolulu, United States (Active)
Researchers
- Principal investigator: Andres, Marilou a. — University of Hawaii at Manoa
- Study coordinator: Andres, Marilou a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.